Lapatinib as a novel HER-2-directed neoadjuvant therapy in inflammatory breast cancer

被引：0
|
作者：
Cristofanilli, Massimo [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER INVESTIGATION | 2007年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [1] HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer
    Verma, Sunil
    Joy, Anil A.
    Rayson, Daniel
    McLeod, Deanna
    Brezden-Masley, Christine
    Boileau, Jean-Francois
    Gelmon, Karen A.
    ONCOLOGIST, 2013, 18 (11): : 1153 - 1166
  • [2] Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly
    J Sun
    S Chia
    British Journal of Cancer, 2017, 116 : 4 - 9
  • [3] Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly
    Sun, J.
    Chia, S.
    BRITISH JOURNAL OF CANCER, 2017, 116 (01) : 4 - 9
  • [4] Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy
    Tsai, Chiaojung Jillian
    Li, Jing
    Gonzalez-Angulo, Ana M.
    Allen, Pamela K.
    Woodward, Wendy A.
    Ueno, Naoto T.
    Lucci, Anthony
    Krishnamurthy, Savitri
    Gong, Yun
    Yang, Wei
    Cristofanilli, Massimo
    Valero, Vicente
    Buchholz, Thomas A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (03): : 242 - 247
  • [5] Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer
    Manguso, Nicholas
    Johnson, Jeffrey
    Basho, Reva Kakkar
    McArthur, Heather L.
    Tanaka, Hisashi
    Giuliano, Armando E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Adjuvant and neoadjuvant therapy with lapatinib in ErbB2-overexpressing breast cancer
    Janni, Wolfgang
    von Minckwitz, Gunter
    Moebus, Volker
    Nitz, Ulrike
    BREAST CARE, 2008, 3 : 17 - 20
  • [7] HER-2-directed, small-molecule antagonists
    Arkin, Michelle
    Moasser, Mark M.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (12) : 1264 - 1276
  • [8] Her-2-directed systemic delivery of fatty acid synthase (FASN) siRNA with novel liposomal carrier systems in the breast cancer mouse model
    Khan, Arif
    Aljarbou, Ahmed N.
    Khan, Shamshir
    Khan, Masood A.
    JOURNAL OF DRUG TARGETING, 2022, 30 (06) : 634 - 645
  • [9] An overview of HER-targeted therapy with lapatinib in breast cancer
    Heather McArthur
    Advances in Therapy, 2009, 26 : 263 - 271
  • [10] Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+operable breast cancer: NSABP protocol B-41
    Robidoux, Andre
    Tang, Gong
    Rastogi, Priya
    Geyer, Charles E.
    Azar, Catherine A.
    Atkins, James Norman
    Fehrenbacher, Louis
    Bear, Harry Douglas
    Baez-Diaz, Luis
    Kuebler, J. Phillip
    Margolese, Richard G.
    Farrar, William Blair
    Brufsky, Adam
    Shibata, Henry R.
    Bandos, Hanna
    Paik, Soonmyung
    Costantino, Joseph P.
    Swain, Sandra M.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345